Press release archives
Seoul, Korea, 2017/09/26 - Seegene, a world's leading developer of multiplex molecular technologies and assays, announced that it has signed a Memorandum of Understanding (MOU) with Hamilton Company, a global leader in the design and manufacture of precision measurement devices, automated liquid handling workstations, and sample management systems. Through this strategic agreement, Seegene and Hamilton will form a robust partnership to develop the Seegene Random Access System.
Steve Hamilton, CEO of Hamilton, said, “We are proud to help enable great companies with innovative technologies such as Seegene’s. We look forward to supporting the promise and excitement of this collaboration.”
The Seegene Random Access System is an innovative molecular diagnostics solution that provides order-to-report on the same day. This capability is enabled by integrating simultaneous and high multiplex real-time PCR testing on Hamilton’s automated liquid handling platforms, regardless of specimen and assay type.
Through the collaboration, Seegene expects to accelerate the development of the Random Access System and to complete the Digitalized Development System, which enables the automation of whole development process from reagent development, clinical studies, manufacturing to quality control.
Dr. Jong Yoon Chun, CEO and founder of Seegene, said “To achieve the Seegene Random Access System, the integration of technologies applied in reagent, instrument and software is necessary. Through our collaboration, we will be able to accelerate the accomplishment of ‘Seegene Random Access System’.” He also emphasized, “Molecular diagnostics testing is currently limited to large hospitals or clinical laboratories; however, with the completion of the system, molecular diagnostics utilization will greatly increase as order-to-report on the same day allows hospitals to conduct molecular diagnosis and this will lead to a breakthrough in achieving on-time customized patient care.”
Seegene(096530, KQ) is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies - DPO™, TOCE™, and MuDT™ - are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies. For more information, please visit www.seegene.com.
Hamilton Company is a global enterprise with affiliates in Reno, Nevada; Franklin, Massachusetts (both USA); and Bonaduz, Switzerland and sales offices throughout the world. Hamilton Company and its affiliated entities are an industry leader in the design and manufacture of liquid handling, process analytics, robotics and automated storage solutions. For more than 60 years, Hamilton Company has been satisfying customer needs by combining quality materials with skilled workmanship to ensure the highest level of performance. Hamilton Company’s lifelong commitment to precision and quality has earned us global ISO 9001 Certification. For more information, visit www.hamiltoncompany.com/robotics
Yoon Chung (email@example.com, Tel: 82-2-2240-4082)
Tyler Kim (firstname.lastname@example.org, Tel: 82-2-2240-4025)
|Previous||Seegene accelerates ‘Project 100’ by securing 30 co-development partners||2017.08.31|
|Next||Seegene develops world’s first multiplex MDx assays with its AI system|